Giuseppe
Emeritus
Vaccine. 2009 Nov 17. [Epub ahead of print]
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
Patel SM, Atmar RL, Sahly HE, Cate TR, Keitel WA. - Baylor College of Medicine, Medicine - Infectious Diseases, BCM MS 280, One Baylor Plaza, Houston, TX 77030, United States.
In a phase I clinical trial, one hundred healthy young adults were randomized to receive two doses 28 days apart of an inactivated, subvirion vaccine containing 15 or 45mug of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route, or 3 or 9mug of H5 HA by the intradermal(ID) route. Seventy-seven subjects received a third dose. All regimens were safe and well tolerated. Antibody responses after two or three doses were low (<=20% or <=38%, respectively) and similar in groups given 3 or 9mug ID or 15mug IM, and were significantly lower than those given 45mug IM. Higher dosages of H5 HA and/or inclusion of adjuvant will be required to enhance immunogenicity by the ID route.
PMID: 19931380 [PubMed - as supplied by publisher]
-
------
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
Patel SM, Atmar RL, Sahly HE, Cate TR, Keitel WA. - Baylor College of Medicine, Medicine - Infectious Diseases, BCM MS 280, One Baylor Plaza, Houston, TX 77030, United States.
In a phase I clinical trial, one hundred healthy young adults were randomized to receive two doses 28 days apart of an inactivated, subvirion vaccine containing 15 or 45mug of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route, or 3 or 9mug of H5 HA by the intradermal(ID) route. Seventy-seven subjects received a third dose. All regimens were safe and well tolerated. Antibody responses after two or three doses were low (<=20% or <=38%, respectively) and similar in groups given 3 or 9mug ID or 15mug IM, and were significantly lower than those given 45mug IM. Higher dosages of H5 HA and/or inclusion of adjuvant will be required to enhance immunogenicity by the ID route.
PMID: 19931380 [PubMed - as supplied by publisher]
-
------